Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,200

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Open access
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L.D., Newbold, K., Papotti, M.G., Berruti, A.·2019·Annals of Oncology
DOI 10.1093/annonc/mdz400
Open this paper in CoChat — free account

Abstract

This ESMO Clinical Practice Guidelines provide updated state-of-the-art recommendations on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a multidisciplinary author panel and accompanied by level of evidence and grade of recommendation, depending on the strength of supporting data and magnitude of benefit from particular interventions

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz400

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 156

  1. 2019, European Network of Cancer Registries Factsheets
  2. Kitahara, 2016, The changing incidence of thyroid cancer, Nat Rev Endocrinol, 12, 646, 10.1038/nrendo.2016.110 · DOI · Paper page
  3. Dal Maso, 2017, Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5, Eur J Cancer, 77, 140, 10.1016/j.ejca.2017.02.023 · DOI
  4. Bibbins-Domingo, 2017, Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 1882, 10.1001/jama.2017.4011 · DOI · Paper page
  5. Pacini, 2006, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium, Eur J Endocrinol, 154, 787, 10.1530/eje.1.02158 · DOI · Paper page
  6. Pacini, 2018, Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies, J Endocrinol Invest, 41, 849, 10.1007/s40618-018-0884-2 · DOI · Paper page
  7. Cibas, 2009, The Bethesda system for reporting thyroid cytopathology, Am J Clin Pathol, 132, 658, 10.1309/AJCPPHLWMI3JV4LA · DOI · Paper page
  8. Maletta, 2016, Cytological features of “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology, Hum Pathol, 54, 134, 10.1016/j.humpath.2016.03.014 · doi:10.1016/j.humpath.2016.03.014
  9. Nikiforova, 2018, Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules, Cancer, 124, 1682, 10.1002/cncr.31245 · DOI · Paper page
  10. Nikiforov, 2016, Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors, JAMA Oncol, 2, 1023, 10.1001/jamaoncol.2016.0386 · DOI · Paper page
  11. Williams, 2000, Guest editorial: two proposals regarding the terminology of thyroid tumors, Int J Surg Pathol, 8, 181, 10.1177/106689690000800304 · doi:10.1177/106689690000800304
  12. Asioli, 2010, Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases, Am J Surg Pathol, 34, 44, 10.1097/PAS.0b013e3181c46677 · DOI · Paper page
  13. Volante, 2007, Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach, Am J Surg Pathol, 31, 1256, 10.1097/PAS.0b013e3180309e6a · DOI · Paper page
  14. 2014, Integrated genomic characterization of papillary thyroid carcinoma, Cell, 159, 676, 10.1016/j.cell.2014.09.050 · DOI · Paper page
  15. Ibrahimpasic, 2017, Genomic alterations in fatal forms of non-anaplastic thyroid cancer: identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence, Clin Cancer Res, 23, 5970, 10.1158/1078-0432.CCR-17-1183 · DOI
  16. Landa, 2016, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers, J Clin Invest, 126, 1052, 10.1172/JCI85271 · DOI · Paper page
  17. Pozdeyev, 2018, Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers, Clin Cancer Res, 24, 3059, 10.1158/1078-0432.CCR-18-0373 · DOI · Paper page
  18. Grani, 2018, Follicular thyroid cancer and Hurthle cell carcinoma: challenges in diagnosis, treatment, and clinical management, Lancet Diabetes Endocrinol, 6, 500, 10.1016/S2213-8587(17)30325-X · DOI · Paper page
  19. Moon, 2017, Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis, Thyroid, 27, 651, 10.1089/thy.2016.0350 · DOI · Paper page
  20. Vuong, 2017, Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-a meta-analysis, Clin Endocrinol (Oxf), 87, 411, 10.1111/cen.13413 · DOI
  21. Castagna, 2011, Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients, Eur J Endocrinol, 165, 441, 10.1530/EJE-11-0466 · DOI · Paper page
  22. Momesso, 2016, Dynamic risk stratification in patients with differentiated thyroid cancer treated without radioactive iodine, J Clin Endocrinol Metab, 101, 2692, 10.1210/jc.2015-4290 · DOI
  23. Park, 2017, Dynamic risk stratification for predicting recurrence in patients with differentiated thyroid cancer treated without radioactive iodine remnant ablation therapy, Thyroid, 27, 524, 10.1089/thy.2016.0477 · DOI
  24. Tuttle, 2010, Thyroid, 20, 1341, 10.1089/thy.2010.0178 · DOI · Paper page
  25. Ito, 2018, Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials, Eur J Surg Oncol, 44, 307, 10.1016/j.ejso.2017.03.004 · DOI · Paper page
  26. Miyauchi, 2018, Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance, Surgery, 163, 48, 10.1016/j.surg.2017.03.028 · DOI
  27. Adam, 2014, Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients, Ann Surg, 260, 601, 10.1097/SLA.0000000000000925 · DOI · Paper page
  28. Bilimoria, 2007, Extent of surgery affects survival for papillary thyroid cancer, Ann Surg, 246, 375, 10.1097/SLA.0b013e31814697d9 · DOI · Paper page
  29. Randolph, 2011, The surgical management of goiter: Part II. Surgical treatment and results, Laryngoscope, 121, 68, 10.1002/lary.21091 · doi:10.1002/lary.21091
  30. Hauch, 2014, Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons, Ann Surg Oncol, 21, 3844, 10.1245/s10434-014-3846-8 · DOI · Paper page
  31. Zhao, 2017, Evaluating the effectiveness of prophylactic central neck dissection with total thyroidectomy for cN0 papillary thyroid carcinoma: an updated meta-analysis, Eur J Surg Oncol, 43, 1989, 10.1016/j.ejso.2017.07.008 · DOI
  32. Hughes, 2018, Prophylactic central compartment neck dissection in papillary thyroid cancer and effect on locoregional recurrence, Ann Surg Oncol, 25, 2526, 10.1245/s10434-018-6528-0 · DOI
  33. Chen, 2018, Prophylactic central neck dissection for papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes: a systematic review and meta-analysis, World J Surg, 42, 2846, 10.1007/s00268-018-4547-4 · DOI
  34. Barczynski, 2013, Prophylactic central neck dissection for papillary thyroid cancer, Br J Surg, 100, 410, 10.1002/bjs.8985 · DOI · Paper page
  35. Pacini, 2006, Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study, J Clin Endocrinol Metab, 91, 926, 10.1210/jc.2005-1651 · DOI · Paper page
  36. Luster, 2008, Guidelines for radioiodine therapy of differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 35, 1941, 10.1007/s00259-008-0883-1 · DOI · Paper page
  37. Lamartina, 2015, Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature, J Clin Endocrinol Metab, 100, 1748, 10.1210/jc.2014-3882 · DOI
  38. Durante, 2010, Identification and optimal postsurgical follow-up of patients with very low-risk papillary thyroid microcarcinomas, J Clin Endocrinol Metab, 95, 4882, 10.1210/jc.2010-0762 · DOI
  39. Verburg, 2016, Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 43, 1001, 10.1007/s00259-016-3327-3 · DOI
  40. Tuttle, 2019, Thyroid, 29, 461, 10.1089/thy.2018.0597 · DOI · Paper page
  41. Schlumberger, 2012, Strategies of radioiodine ablation in patients with low-risk thyroid cancer, N Engl J Med, 366, 1663, 10.1056/NEJMoa1108586 · DOI · Paper page
  42. Mallick, 2012, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer, N Engl J Med, 366, 1674, 10.1056/NEJMoa1109589 · DOI · Paper page
  43. Schlumberger, 2018, Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial, Lancet Diabetes Endocrinol, 6, 618, 10.1016/S2213-8587(18)30113-X · DOI · Paper page
  44. Dehbi, 2019, Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial, Lancet Diabetes Endocrinol, 7, 44, 10.1016/S2213-8587(18)30306-1 · DOI
  45. Lamartina, 2018, Recent advances in managing differentiated thyroid cancer, F1000Res, 7, 86., 10.12688/f1000research.12811.1 · doi:10.12688/f1000research.12811.1
  46. Giovanella, 2014, Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper, Eur J Endocrinol, 171, R33, 10.1530/EJE-14-0148 · DOI
  47. Spencer, 2011, Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC), J Clin Endocrinol Metab, 96, 3615, 10.1210/jc.2011-1740 · DOI
  48. Crocetti, 2008, Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients, Thyroid, 18, 1049, 10.1089/thy.2008.0160 · DOI
  49. Brassard, 2011, Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients, J Clin Endocrinol Metab, 96, 1352, 10.1210/jc.2010-2708 · DOI · Paper page
  50. Durante, 2012, Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?, J Clin Endocrinol Metab, 97, 2748, 10.1210/jc.2012-1123 · DOI · Paper page
  51. Angell, 2014, In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation, Thyroid, 24, 1127, 10.1089/thy.2013.0691 · DOI
  52. Grani, 2014, Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy, J Clin Endocrinol Metab, 99, 1970, 10.1210/jc.2014-1098 · DOI
  53. Torlontano, 2004, Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases, J Clin Endocrinol Metab, 89, 3402, 10.1210/jc.2003-031521 · DOI
  54. Grani, 2018, Interobserver agreement of various thyroid imaging reporting and data systems, Endocr Connect, 7, 1, 10.1530/EC-17-0336 · DOI · Paper page
  55. Lamartina, 2016, Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer, J Clin Endocrinol Metab, 101, 3036, 10.1210/jc.2016-1440 · DOI
  56. Leboulleux, 2007, Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer, J Clin Endocrinol Metab, 92, 3590, 10.1210/jc.2007-0444 · DOI · Paper page
  57. Leenhardt, 2013, 2013 European Thyroid Association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer, Eur Thyroid J, 2, 147, 10.1159/000354537 · DOI · Paper page
  58. Lamartina, 2016, ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach, Eur J Endocrinol, 175, R185, 10.1530/EJE-16-0088 · doi:10.1530/eje-16-0088
  59. Leboulleux, 2007, The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers, Nat Rev Endocrinol, 3, 112, 10.1038/ncpendmet0402 · DOI
  60. Robbins, 2006, Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning, J Clin Endocrinol Metab, 91, 498, 10.1210/jc.2005-1534 · DOI · Paper page
  61. Nascimento, 2015, Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer, Thyroid, 25, 437, 10.1089/thy.2014.0320 · DOI
  62. Deandreis, 2011, Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?, Endocr Relat Cancer, 18, 159, 10.1677/ERC-10-0233 · DOI · Paper page
  63. Robbins, 2008, The value of positron emission tomography (PET) in the management of patients with thyroid cancer, Best Pract Res Clin Endocrinol Metab, 22, 1047, 10.1016/j.beem.2008.10.001 · doi:10.1016/j.beem.2008.10.001
  64. Terroir, 2017, The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer, Eur J Nucl Med Mol Imaging, 44, 638, 10.1007/s00259-016-3551-x · doi:10.1007/s00259-016-3551-x
  65. Grani, 2019, Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound, J Clin Endocrinol Metab, 104, 4981, 10.1210/jc.2019-00962 · DOI
  66. Miyauchi, 2011, Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy, Thyroid, 21, 707, 10.1089/thy.2010.0355 · DOI · Paper page
  67. Durante, 2006, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy, J Clin Endocrinol Metab, 91, 2892, 10.1210/jc.2005-2838 · DOI · Paper page
  68. Osorio, 2017, Systematic review of site distribution of bone metastases in differentiated thyroid cancer, Head Neck, 39, 812, 10.1002/hed.24655 · DOI
  69. Ruegemer, 1988, Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables, J Clin Endocrinol Metab, 67, 501, 10.1210/jcem-67-3-501 · DOI · Paper page
  70. Schlumberger, 2014, Definition and management of radioactive iodine-refractory differentiated thyroid cancer, Lancet Diabetes Endocrinol, 2, 356, 10.1016/S2213-8587(13)70215-8 · DOI · Paper page
  71. McGriff, 2002, Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer, Ann Med, 34, 554, 10.1080/078538902321117760 · DOI
  72. Sugitani, 2010, Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial, J Clin Endocrinol Metab, 95, 4576, 10.1210/jc.2010-0161 · DOI
  73. Carhill, 2015, Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012, J Clin Endocrinol Metab, 100, 3270, 10.1210/JC.2015-1346 · DOI · Paper page
  74. Deandreis, 2017, Comparison of empiric versus whole-body/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer, J Nucl Med, 58, 717, 10.2967/jnumed.116.179606 · DOI
  75. Falchook, 2015, BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer, Thyroid, 25, 71, 10.1089/thy.2014.0123 · DOI · Paper page
  76. Dunn, 2019, Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers, J Clin Endocrinol Metab, 104, 1417, 10.1210/jc.2018-01478 · DOI
  77. Ho, 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer, N Engl J Med, 368, 623, 10.1056/NEJMoa1209288 · DOI · Paper page
  78. Mazziotti, 2018, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience, Endocrine, 59, 90, 10.1007/s12020-017-1455-6 · DOI
  79. Choksi, 2017, Skeletal complications and mortality in thyroid cancer: a population-based study, J Clin Endocrinol Metab, 102, 1254, 10.1210/jc.2016-3906 · doi:10.1210/jc.2016-3906
  80. Wexler, 2011, Approach to the thyroid cancer patient with bone metastases, J Clin Endocrinol Metab, 96, 2296, 10.1210/jc.2010-1996 · DOI
  81. Hamadeh, 2015, Drug induced osteonecrosis of the jaw, Cancer Treat Rev, 41, 455, 10.1016/j.ctrv.2015.04.007 · DOI
  82. Drost, 2017, Efficacy of postoperative radiation treatment for bone metastases in the extremities, Radiother Oncol, 124, 45, 10.1016/j.radonc.2017.05.010 · doi:10.1016/j.radonc.2017.05.010
  83. Deschamps, 2014, Percutaneous ablation of bone tumors, Diagn Interv Imaging, 95, 659, 10.1016/j.diii.2014.04.004 · doi:10.1016/j.diii.2014.04.004
  84. George, 2015, Interventions for the treatment of metastatic extradural spinal cord compression in adults, Cochrane Database Syst Rev, CD006716
  85. Deschamps, 2016, Percutaneous osteosynthesis in the pelvis in cancer patients, Eur Radiol, 26, 1631, 10.1007/s00330-015-3971-1 · doi:10.1007/s00330-015-3971-1
  86. de Baere, 2015, Interventional oncology for liver and lung metastases from colorectal cancer: the current state of the art, Diagn Interv Imaging, 96, 647, 10.1016/j.diii.2015.04.004 · doi:10.1016/j.diii.2015.04.004
  87. Venkatanarasimha, 2017, Radioembolisation of hepatocellular carcinoma: a primer, Clin Radiol, 72, 1002, 10.1016/j.crad.2017.07.021 · doi:10.1016/j.crad.2017.07.021
  88. Sabra, 2017, Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma, Cancer, 123, 2955, 10.1002/cncr.30690 · DOI
  89. Brose, 2014, Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial, Lancet, 384, 319, 10.1016/S0140-6736(14)60421-9 · DOI · Paper page
  90. Schlumberger, 2015, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer, N Engl J Med, 372, 621, 10.1056/NEJMoa1406470 · DOI · Paper page
  91. Robinson, 2016, Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer, J Clin Endocrinol Metab, 101, 4103, 10.1210/jc.2015-3989 · DOI
  92. Brose, 2017, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial, J Clin Oncol, 35, 2692, 10.1200/JCO.2016.71.6472 · DOI
  93. Berdelou, 2018, Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice, Thyroid, 28, 72, 10.1089/thy.2017.0205 · DOI
  94. Balmelli, 2018, Lenvatinib in advanced radioiodine-refractory thyroid cancer—a retrospective analysis of the Swiss Lenvatinib Named Patient Program, J Cancer, 9, 250, 10.7150/jca.22318 · doi:10.7150/jca.22318
  95. Cohen, 2008, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study, J Clin Oncol, 26, 4708, 10.1200/JCO.2007.15.9566 · DOI · Paper page
  96. Locati, 2014, Treatment of advanced thyroid cancer with axitinib: phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments, Cancer, 120, 2694, 10.1002/cncr.28766 · DOI
  97. Cabanillas, 2017, Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: results of a multicenter phase II international thyroid oncology group trial, J Clin Oncol, 35, 3315, 10.1200/JCO.2017.73.0226 · DOI
  98. Brose, 2018, A phase 2 trial of cabozantinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma in the first-line setting, Int J Radiat Oncol Biol Phys, 100, 1311, 10.1016/j.ijrobp.2017.12.028 · doi:10.1016/j.ijrobp.2017.12.028
  99. Schlumberger, 2018, A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209, J Clin Oncol, 36, 6021., 10.1200/JCO.2018.36.15_suppl.6021 · doi:10.1200/jco.2018.36.15_suppl.6021
  100. Bible, 2010, Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study, Lancet Oncol, 11, 962, 10.1016/S1470-2045(10)70203-5 · DOI · Paper page
  101. Carr, 2010, Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation, Clin Cancer Res, 16, 5260, 10.1158/1078-0432.CCR-10-0994 · DOI · Paper page
  102. Leboulleux, 2012, Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial, Lancet Oncol, 13, 897, 10.1016/S1470-2045(12)70335-2 · DOI · Paper page
  103. Brose, 2016, Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 1272, 10.1016/S1470-2045(16)30166-8 · DOI · Paper page
  104. French, 2017, Leveraging the immune system to treat advanced thyroid cancers, Lancet Diabetes Endocrinol, 5, 469, 10.1016/S2213-8587(16)30277-7 · DOI
  105. Haddad, 2017, Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes, Endocrine, 56, 121, 10.1007/s12020-017-1233-5 · DOI
  106. Subbiah, 2018, Selective RET kinase inhibition for patients with RET-altered cancers, Ann Oncol, 29, 1869, 10.1093/annonc/mdy137 · DOI · Paper page
  107. Capdevila, 2018, Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer, Cancer Treat Rev, 69, 164, 10.1016/j.ctrv.2018.06.019 · DOI
  108. Tahara, 2019, Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer, Eur J Cancer, 106, 61, 10.1016/j.ejca.2018.10.002 · DOI
  109. Oktay, 2018, Fertility preservation in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol, 36, 1994, 10.1200/JCO.2018.78.1914 · DOI · Paper page
  110. Nagaiah, 2011, Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment, J Oncol, 2011, 1, 10.1155/2011/542358 · DOI · Paper page
  111. Bogsrud, 2008, 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma, Thyroid, 18, 713, 10.1089/thy.2007.0350 · doi:10.1089/thy.2007.0350
  112. Sugitani, 2018, Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan, J Nippon Med Sch, 85, 18, 10.1272/jnms.2018_85-3 · doi:10.1272/jnms.2018_85-3
  113. Baek, 2017, Role of surgery in the management of anaplastic thyroid carcinoma: Korean nationwide multicenter study of 329 patients with anaplastic thyroid carcinoma, 2000 to 2012, Head Neck, 39, 133, 10.1002/hed.24559 · doi:10.1002/hed.24559
  114. Ito, 2012, Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumors, Head Neck, 34, 230, 10.1002/hed.21721 · doi:10.1002/hed.21721
  115. Kwon, 2016, The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and meta-analysis, Eur J Cancer, 59, 34, 10.1016/j.ejca.2016.02.015 · DOI
  116. Bhatia, 2010, Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy, Head Neck, 32, 829, 10.1002/hed.21257 · doi:10.1002/hed.21257
  117. Sherman, 2011, Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review, Radiother Oncol, 101, 425, 10.1016/j.radonc.2011.09.004 · DOI
  118. Mohebati, 2014, Anaplastic thyroid carcinoma: a 25-year single-institution experience, Ann Surg Oncol, 21, 1665, 10.1245/s10434-014-3545-5 · doi:10.1245/s10434-014-3545-5
  119. Pezzi, 2017, Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base, Cancer, 123, 1653, 10.1002/cncr.30493 · doi:10.1002/cncr.30493
  120. De Crevoisier, 2004, Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy, Int J Radiat Oncol Biol Phys, 60, 1137, 10.1016/j.ijrobp.2004.05.032 · DOI
  121. Wang, 2006, Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens, Cancer, 107, 1786, 10.1002/cncr.22203 · doi:10.1002/cncr.22203
  122. Dandekar, 2009, Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis, Int J Radiat Oncol Biol Phys, 74, 518, 10.1016/j.ijrobp.2008.08.016 · doi:10.1016/j.ijrobp.2008.08.016
  123. Foote, 2011, Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy, Thyroid, 21, 25, 10.1089/thy.2010.0220 · doi:10.1089/thy.2010.0220
  124. Smallridge, 2012, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer, Thyroid, 22, 1104, 10.1089/thy.2012.0302 · DOI · Paper page
  125. Shimaoka, 1985, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma, Cancer, 56, 2155, 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E · DOI · Paper page
  126. Ain, 2000, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group, Thyroid, 10, 587, 10.1089/thy.2000.10.587 · DOI · Paper page
  127. Sosa, 2014, Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma, Thyroid, 24, 232, 10.1089/thy.2013.0078 · DOI
  128. Tahara, 2017, Lenvatinib for anaplastic thyroid cancer, Front Oncol, 7, 25., 10.3389/fonc.2017.00025 · DOI
  129. Cabanillas, 2018, Recent advances and emerging therapies in anaplastic thyroid carcinoma [version 1; referees: 3 approved], F1000Res, 7, 87, 10.12688/f1000research.13124.1 · DOI
  130. Subbiah, 2018, Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer, J Clin Oncol, 36, 7, 10.1200/JCO.2017.73.6785 · DOI · Paper page
  131. Wirth, 2018, Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer, J Clin Oncol, 36, 6024, 10.1200/JCO.2018.36.15_suppl.6024 · doi:10.1200/jco.2018.36.15_suppl.6024
  132. Agrawal, 2013, Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS, J Clin Endocrinol Metab, 98, E364, 10.1210/jc.2012-2703 · DOI · Paper page
  133. Elisei, 2013, 2012 European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer, Eur Thyroid J, 1, 216, 10.1159/000346174 · DOI
  134. Wells, 2015, Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma, Thyroid, 25, 567, 10.1089/thy.2014.0335 · DOI · Paper page
  135. Romei, 2016, New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double, J Med Genet, 53, 729, 10.1136/jmedgenet-2016-103833 · DOI
  136. Costante, 2007, Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules, J Clin Endocrinol Metab, 92, 450, 10.1210/jc.2006-1590 · DOI · Paper page
  137. Costante, 2009, Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls, Nat Rev Endocrinol, 5, 35, 10.1038/ncpendmet1023 · DOI
  138. Machens, 2010, Biomarker-based risk stratification for previously untreated medullary thyroid cancer, J Clin Endocrinol Metab, 95, 2655, 10.1210/jc.2009-2368 · DOI · Paper page
  139. Barbet, 2005, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma, J Clin Endocrinol Metab, 90, 6077, 10.1210/jc.2005-0044 · DOI · Paper page
  140. Laure Giraudet, 2008, Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times, Eur J Endocrinol, 158, 239, 10.1530/EJE-07-0667 · DOI · Paper page
  141. Meijer, 2010, Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis, Clin Endocrinol (Oxf), 72, 534, 10.1111/j.1365-2265.2009.03666.x · DOI
  142. Hadoux, 2016, Management of advanced medullary thyroid cancer, Lancet Diabetes Endocrinol, 4, 64, 10.1016/S2213-8587(15)00337-X · DOI
  143. Moley, 1999, Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection, Ann Surg, 229, 880, 10.1097/00000658-199906000-00016 · doi:10.1097/00000658-199906000-00016
  144. Treglia, 2012, PET imaging in recurrent medullary thyroid carcinoma, Int J Mol Imaging, 2012, 1
  145. Romero-Lluch, 2017, Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff, Eur J Nucl Med Mol Imaging, 44, 2004, 10.1007/s00259-017-3759-4 · doi:10.1007/s00259-017-3759-4
  146. Bodei, 2004, Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas, Cancer Biother Radiopharm, 19, 65, 10.1089/108497804773391694 · doi:10.1089/108497804773391694
  147. Hadoux, 2017, Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer, Best Pract Res Clin Endocrinol Metab, 31, 335, 10.1016/j.beem.2017.04.009 · DOI
  148. Wells, 2012, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial, J Clin Oncol, 30, 134, 10.1200/JCO.2011.35.5040 · DOI · Paper page
  149. Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J Clin Oncol, 31, 3639, 10.1200/JCO.2012.48.4659 · DOI · Paper page
  150. Fox, 2013, Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma, Clin Cancer Res, 19, 4239, 10.1158/1078-0432.CCR-13-0071 · doi:10.1158/1078-0432.ccr-13-0071
  151. Schlumberger, 2017, Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma, Ann Oncol, 28, 2813, 10.1093/annonc/mdx479 · DOI
  152. Trimboli, 2018, Efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to RECIST criteria: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 9, 224., 10.3389/fendo.2018.00224 · doi:10.3389/fendo.2018.00224
  153. Bastholt, 2016, Effect of an outreach programme on vandetanib safety in medullary thyroid cancer, Eur Thyroid J, 5, 187, 10.1159/000448919 · DOI
  154. Iten, 2009, [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial, Cancer, 115, 2052, 10.1002/cncr.24272 · DOI
  155. Cherny, 2017, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, 28, 2340, 10.1093/annonc/mdx310 · DOI · Paper page
  156. Dykewicz, 2001, Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, Clin Infect Dis, 33, 139, 10.1086/321805 · DOI · Paper page

Cited by

See all 1,200

Metadata

Authors
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-12
Volume
30
Issue
12
Pages
1856-1883
ISSN
0923-7534 (ISSN-L)
DOI
10.1093/annonc/mdz400
OpenAlex
W2975387808
Cited by
1,200
References
7
FWCI
67.80
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
ESMO

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. https://app.cochat.ai/papers/10.1093/annonc/mdz400
The paper
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. https://doi.org/10.1093/annonc/mdz400

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.